Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

被引：223
|
作者：
Aldoss, Ibrahim [1 ]
Yang, Dongyun [2 ]
Aribi, Ahmed [1 ]
Ali, Haris [1 ]
Sandhu, Karamjeet [1 ]
Al Malki, Monzr M. [1 ]
Mei, Matthew [1 ]
Salhotra, Amandeep [1 ]
Khaled, Samer [1 ]
Nakamura, Ryotaro [1 ]
Snyder, David [1 ]
O'Donnell, Margaret [1 ]
Stein, Anthony S. [1 ]
Forman, Stephen J. [1 ]
Marcucci, Guido [1 ]
Pullarkat, Vinod [1 ]
机构：
[1] City Hope Natl Med Ctr, Gehr Family Ctr Leukemia Res, Dept Hematol & Hematopoiet Cell Transplant, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Informat Sci, Div Biostat, Duarte, CA USA
来源：
HAEMATOLOGICA | 2018年 / 103卷 / 09期
关键词：
CONVENTIONAL CARE REGIMENS; OLDER PATIENTS; AZACITIDINE; AML; RECOMMENDATIONS; DIAGNOSIS; TARGETS;
D O I：
10.3324/haematol.2018.188094
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E404 / E407
页数：4
相关论文
共 50 条
  • [31] Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant
    Ionescu, Filip
    David, Jerel C.
    Ravichandran, Apoorva
    Sallman, David A.
    Sweet, Kendra
    Komrokji, Rami S.
    Chan, Onyee
    Kuykendall, Andrew
    Padron, Eric
    Faramand, Rawan
    Bejanyan, Nelli
    Khimani, Farhad
    Elmariah, Hany
    Pidala, Joseph
    Mishra, Asmita
    Perez, Lia
    Nishihori, Taiga
    Lancet, Jeffrey E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (06): : 400 - 406
  • [32] Chidamide in Combination With DCAG With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia
    Liu, Qingyang
    Zhang, Xiawei
    Lv, Lei
    Xu, Linming
    Jing, Yu
    Gao, Wenjing
    Wang, Lili
    Dou, Liping
    CANCER MEDICINE, 2025, 14 (05):
  • [33] Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
    Bewersdorf, Jan Philipp
    Giri, Smith
    Wang, Rong
    Williams, Robert T.
    Tallman, Martin S.
    Zeidan, Amer M.
    Stahl, Maximilian
    HAEMATOLOGICA, 2020, 105 (11) : 2659 - 2663
  • [34] Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies
    Feld, Jonathan
    Tremblay, Douglas
    Dougherty, Mikaela
    Czaplinska, Tina
    Sanchez, Gillian
    Brady, Claudia
    Kremyanskaya, Marina
    Bar-Natan, Michal
    Keyzner, Alla
    Marcellino, Bridget K.
    Gabrilove, Janice
    Navada, Shyamala C.
    Silverman, Lewis R.
    El Jamal, Siraj M.
    Mascarenhas, John
    Shih, Alan H.
    HEMASPHERE, 2021, 5 (04):
  • [35] Venetoclax with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting
    Piccini, Matteo
    Pilerci, Sofia
    Scappini, Barbara
    Bencini, Sara
    Peruzzi, Benedetta
    Caporale, Roberto
    Signori, Leonardo
    Fabiana, Pancani
    Maria, Vannucchi Alessandro
    Gianfaldoni, Giacomo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S289 - S289
  • [36] A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
    Bang, Su-Yeon
    Park, Silvia
    Kwag, Daehun
    Lee, Jong Hyuk
    Min, Gi-June
    Park, Sung-Soo
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Lee, Seok
    Min, Chang-Ki
    Cho, Seok-Goo
    Lee, Jong Wook
    Kim, Hee-Je
    CANCERS, 2023, 15 (06)
  • [37] THE USE OF VENETOCLAX WITH HYPOMETHYLATING AGENTS (HMAS) FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN A REAL-LIFE SETTING: THE BOLOGNA EXPERIENCE
    Nanni, J.
    Cristiano, G.
    Marconi, G.
    Parisi, S.
    Sartor, C.
    Ottaviani, E.
    Baldini, L.
    Testoni, N.
    Baldazzi, C.
    Paolini, S.
    Cavo, M.
    Papayannidis, C.
    Curti, A.
    HAEMATOLOGICA, 2019, 104 : 137 - 137
  • [38] Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study
    Ron Ram
    Odelia Amit
    Tsila Zuckerman
    Ronit Gurion
    Pia Raanani
    Yael Bar-On
    Irit Avivi
    Ofir Wolach
    Annals of Hematology, 2019, 98 : 1927 - 1932
  • [39] Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience
    Gaut, Daria
    Burkenroad, Aaron
    Duong, Tuyen
    Feammelli, Jesse
    Sasine, Joshua
    Schiller, Gary
    LEUKEMIA RESEARCH, 2020, 90
  • [40] AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia
    Todisco, Elisabetta
    Papayannidis, Cristina
    Fracchiolla, Nicola
    Petracci, Elisabetta
    Zingaretti, Chiara
    Vetro, Calogero
    Martelli, Maria Paola
    Zappasodi, Patrizia
    Di Renzo, Nicola
    Gallo, Susanna
    Audisio, Ernesta
    Griguolo, Davide
    Cerchione, Claudio
    Selleri, Carmine
    Mattei, Daniele
    Bernardi, Massimo
    Fumagalli, Monica
    Rizzuto, Giuliana
    Facchini, Luca
    Basilico, Claudia Maria
    Manfra, Ilenia
    Borlenghi, Erika
    Cairoli, Roberto
    Salutari, Prassede
    Gottardi, Michele
    Molteni, Alfredo
    Martini, Vincenza
    Lunghi, Monia
    Fianchi, Luana
    Cilloni, Daniela
    Lanza, Francesco
    Abruzzese, Elisabetta
    Cascavilla, Nicola
    Rivellini, Flavia
    Ferrara, Felicetto
    Maurillo, Luca
    Nanni, Jacopo
    Romano, Alessandra
    Cardinali, Valeria
    Gigli, Federica
    Roncoroni, Elisa
    Federico, Vincenzo
    Marconi, Giovanni
    Volpi, Roberta
    Sciume, Mariarita
    Tarella, Corrado
    Rossi, Giuseppe
    Martinelli, Giovanni
    CANCER, 2023, 129 (07) : 992 - 1004
12345